Helena Teede1, Melanie Gibson-Helm, Robert J Norman, Jacqueline Boyle. 1. Women's Public Health Research (H.T., M.G.-H., J.B.), Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton 3168, Victoria, Australia; Diabetes and Vascular Medicine Unit (H.T.), Monash Health, Clayton 3168, Victoria, Australia; and The Robinson Institute (R.J.N.), The University of Adelaide, North Adelaide SA 5006, South Australia, Australia.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is an under-recognized, common, and complex endocrinopathy. The name PCOS is a misnomer, and there have been calls for a change to reflect the broader clinical syndrome. OBJECTIVE: The aim of the study was to determine perceptions held by women and primary health care physicians around key clinical features of PCOS and attitudes toward current and alternative names for the syndrome. DESIGN: We conducted a cross-sectional study utilizing a devised questionnaire. SETTING: Participants were recruited throughout Australia via professional associations, women's health organizations, and a PCOS support group. PARTICIPANTS: Fifty-seven women with PCOS and 105 primary care physicians participated in the study. MAIN OUTCOME MEASURES: Perceptions of key clinical PCOS features and attitudes toward current and alternative syndrome names were investigated. RESULTS: Irregular periods were identified as a key clinical feature of PCOS by 86% of the women with PCOS and 90% of the primary care physicians. In both groups, 60% also identified hormone imbalance as a key feature. Among women with PCOS, 47% incorrectly identified ovarian cysts as key, 48% felt the current name is confusing, and 51% supported a change. Most primary care physicians agreed that the name is confusing (74%) and needs changing (81%); however, opinions on specific alternative names were divided. CONCLUSIONS: The name "polycystic ovary syndrome" is perceived as confusing, and there is general support for a change to reflect the broader clinical syndrome. Engagement of primary health care physicians and consumers is strongly recommended to ensure that an alternative name enhances understanding and recognition of the syndrome and its complex features.
CONTEXT: Polycystic ovary syndrome (PCOS) is an under-recognized, common, and complex endocrinopathy. The name PCOS is a misnomer, and there have been calls for a change to reflect the broader clinical syndrome. OBJECTIVE: The aim of the study was to determine perceptions held by women and primary health care physicians around key clinical features of PCOS and attitudes toward current and alternative names for the syndrome. DESIGN: We conducted a cross-sectional study utilizing a devised questionnaire. SETTING:Participants were recruited throughout Australia via professional associations, women's health organizations, and a PCOS support group. PARTICIPANTS: Fifty-seven women with PCOS and 105 primary care physicians participated in the study. MAIN OUTCOME MEASURES: Perceptions of key clinical PCOS features and attitudes toward current and alternative syndrome names were investigated. RESULTS: Irregular periods were identified as a key clinical feature of PCOS by 86% of the women with PCOS and 90% of the primary care physicians. In both groups, 60% also identified hormone imbalance as a key feature. Among women with PCOS, 47% incorrectly identified ovarian cysts as key, 48% felt the current name is confusing, and 51% supported a change. Most primary care physicians agreed that the name is confusing (74%) and needs changing (81%); however, opinions on specific alternative names were divided. CONCLUSIONS: The name "polycystic ovary syndrome" is perceived as confusing, and there is general support for a change to reflect the broader clinical syndrome. Engagement of primary health care physicians and consumers is strongly recommended to ensure that an alternative name enhances understanding and recognition of the syndrome and its complex features.
Authors: Susan Arentz; Jason Anthony Abbott; Caroline Anne Smith; Alan Bensoussan Journal: BMC Complement Altern Med Date: 2014-12-18 Impact factor: 3.659
Authors: Salla Karjula; Laure Morin-Papunen; Juha Auvinen; Aimo Ruokonen; Katri Puukka; Stephen Franks; Marjo-Riitta Järvelin; Juha S Tapanainen; Jari Jokelainen; Jouko Miettunen; Terhi T Piltonen Journal: J Clin Endocrinol Metab Date: 2017-06-01 Impact factor: 5.958
Authors: Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman Journal: Hum Reprod Date: 2018-09-01 Impact factor: 6.918
Authors: Ali Abbara; Pei Chia Eng; Maria Phylactou; Sophie A Clarke; Tia Hunjan; Rachel Roberts; Sunitha Vimalesvaran; George Christopoulos; Rumana Islam; Kate Purugganan; Alexander N Comninos; Geoffrey H Trew; Rehan Salim; Artsiom Hramyka; Lisa Owens; Tom Kelsey; Waljit S Dhillo Journal: Front Endocrinol (Lausanne) Date: 2019-09-26 Impact factor: 5.555